The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

Centre for Eye Research Australia0 sites20 target enrollmentMay 1, 2015

Overview

No summary available.

Registry

who.int

Start Date

May 1, 2015

End Date

February 1, 2019

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Age greater than or equal to18 years
•2\. CRVO with cystoid macular as determined by fluorescein angiography and duration of onset less than 12 months
•3\. Best\-corrected visual acuity (BCVA) of 17\-70 letters (6/12 –6/120\)
•4\. Central macular thickness of greater than or equal to 300 microns as measured by Heidelberg Optical coherence tomography.
•5\. Absent relative afferent pupillary defect

•1\. Uncontrolled blood pressure (greater than or equal to180 mmHg, systolic and 110 mmHg, diastolic)
•2\. Chronic renal failure
•3\. Major surgery within one month of study
•4\. Previous systemic anti\-VEGF treatment
•5\. Women of childbearing potential not using adequate contraception and women who are breast feeding
•6\. Intercurrent severe disease such as septicaemia
•1\. Glaucoma which is uncontrolled with intraocular pressure\-lowering medications
•2\. Past history of severe steroid response with IOP greater than or equal to 35 mmHg following steroid treatment
•3\. Loss of vision due to other causes (e.g. age\-related macular degeneration, myopic macular degeneration)
•4\. VA of \<6/60 in the fellow eye